A blood and urine cfDNA methylation assay for breast cancer prognosis prediction and treatment monitoring is being assessed with Dr. Carol Nishikubo, Adjunct Medical Oncology, Santa Monica Hematology, SJHC, PHS.

The objective is to monitor patients receiving current approved therapies for breast cancer.